Correction to: Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia
Tawfeg Ben‐Omran(Qatar Airways (Qatar)), Raúl D. Santos(Universidade de São Paulo), Allan M. Lund(Copenhagen University Hospital), Genovefa Kolovou(Onassis Cardiac Surgery Center), Francisco J. Nóvoa(Universidad de Las Palmas de Gran Canaria), Rosa M. Sánchez-Hernández(Hospital Universitario Insular de Gran Canaria), L. Masana(Universitat Rovira i Virgili), Daiana Ibarretxe(Hospital Universitari Sant Joan de Reus), Maria Lúcia Góes Araujo(Garrahan Hospital), Gema Ariceta(Hospital de Cruces), Osamah Hussein(Bar-Ilan University), Martin P. Bogsrud(Oslo University Hospital)
Cited by 0
Related Papers
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2017|3.8k
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society
|European Heart Journal|2013|2.7k
Lipoprotein(a) as a cardiovascular risk factor: current status
|European Heart Journal|2010|1.8k